Selinexor—A Drug Review
Selinexor developed by Karyopharm Therapeutics is the first orally available small-molecule inhibitor of exportin-1 (XPO1). XPO-1 is a protein transporter responsible for the export of macromolecules such as tumor suppressor proteins and oncoprotein mRNAs from the nucleus to the cytoplasm; its inhibition results in blocking of multiple oncogenic pathways. Overexpression of XPO1 is seen in multiple myeloma and various other malignancies and is a poor prognostic marker. Pivotal positive trials have resulted in the approval of selinexor for use in refractory or relapsed diffuse large B cell lymphoma and multiple myeloma. In this review, we briefly cover the drug development, mechanism of action, indications, and toxicities of the drug, and the major pivotal trials.
Artikel online veröffentlicht:
26. November 2021
© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Syed YY. Selinexor: first global approval. Drugs 2019; 79 (13) 1485-1494
- 2 Pinto V, Bergantim R, Caires HR, Seca H, Guimarães JE, Vasconcelos MH. Multiple myeloma: available therapies and causes of drug resistance. Cancers Basel 2020; 12 (02) 407
- 3 Karyopharm Therapeutics. Karyopharm announces FDA approval of XPOVIO™ (selinexor) or the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL). [media release]. 22 June 2020. Available at http://www.karyopharm.com. Accessed Aug 4, 2021
- 4 Lassman AB, Wen PY, Van Den Bent MJ. et al Efficacy and safety of selinexor in recurrent glioblastoma. J Clin Oncol 2019; 37 (15) 2005 2005 J Clin Oncol 2019; 37(15_suppl): 2005-2005
- 5 Vogl DT, Dingli D, Cornell RF. et al Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 2018; 36 (09) 859-866
- 6 Gandhi UH, Senapedis W, Baloglu E. et al Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin Lymphoma Myeloma Leuk 2018; 18 (05) 335-345
- 7 Chari A, Vogl DT, Gavriatopoulou M. et al Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019; 381 (08) 727-738
- 8 Richter J, Madduri D, Richard S, Chari A. Selinexor in relapsed/refractory multiple myeloma. Ther Adv Hematol 2020; 11: 2040620720930629
- 9 ClinicalTrials.gov. National Library of Medicine (U.S.). (2020, February). Selinexor Treatment for Refractory Myeloma (STORM) (NCT02336815). https://clinicaltrials.gov/ct2/show/results/NCT02336815. Accessed Aug 4, 2021
- 10 Kalakonda N, Maerevoet M, Cavallo F. et al Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020; 7 (07) e511-e522
- 11 ClinicalTrials.gov. National Library of Medicine (U.S.).(2020, May). Bortezomib, Selinexor and Dexamethasone in Multiple Myeloma patients. (BOSTON) (NCT03110562). https://www. clinicaltrials.gov/ct2/show/NCT03110562. Accessed Aug 4, 2021